Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing heterocyclic carbon compound having only o – n – s,...
Reexamination Certificate
1999-08-27
2001-01-30
Lilling, Herbert J. (Department: 1651)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing heterocyclic carbon compound having only o, n, s,...
Reexamination Certificate
active
06180375
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention is directed to the use of microbial biotransformation to O-demethylate certain pharmaceutical intermediate compounds. More specifically, it is directed to the use of certain microoganisms to O-demethylate certain pharmacetical intermediate compounds.
An article in Analytica Chimica Acta(1990) 233, 191-198 refers to the use of
Cunninghamella elegans
to demethylate certain n-propylnoraporphine compounds.
An article in Biomedical and Enviromental Mass Spectrometry (1986) 13, 223-229 refers to the use of
Cunninghamella elegans
to produce potential metabolites of N-n-propyl norapo morphine.
A review article published in Enzyme and Microbial Technology (1984) 6,242-253 at pages 250-252 broadly reviews the use of certain microorganisms, e.g. fungal species such as Cunninghamella, Aspergillus, Thamnostylum, Penicillium and Sepedonium to O-dealkylate certain compounds.
Chapter 5.5 of Biotransformations in Preparative Organic Chemistry by H. G. Davies et al refers to the use of
Sepedonium chrysospermum
and
Cunninghamella elegans
to demethylate certain compounds, including vindoline and 10,11-dimethoxyaporphine.
An article in Phytochemistry (1997) 44 (8), 1479-1482, refers to the use of
Aspergillus niger
to produce (−)-pinoresinol through O-demethylation of (±)-eudesmin.
U.S. Pat. No. 5,618,707 granted Apr. 18, 1997 refers to the use of
Zygosaccharomyces bailii
ATCC 38924 to stereoselectively reduce a pentanoic acid compound to a phenyloxazolidinone product.
U.S. Pat. No. 5,580,764 refers to the use of oxido/reductases from
Lactobacillus plantarum, Pichia haplophila, Candida utilis, Lactobacillus buchmans, Aspergillus flavus
and
Neurospora crassa
to reduce intermediates in the synthesis of carbonic anhydrase inhibitors.
REFERENCES:
patent: 4431736 (1984-02-01), Romesser
Computer Abstract Scisearch Sedlaczek Et Al “Oxidation-Reduction State of the Nicotinamide Nucleotides and the Steroid 11-Alpha Hyudroxylase Activity inMonosporium olivaceumATCC-36300” ACTA Microbio. Polonica (1979) vol. 28. No. 2 pp. 111-121, 1979.
Computer Abstract Caplus Rosati Et Al “Discovery and SAR of a Potent Non-Steroidal Estrogen Agonist, CP-336, 156” ABS 212 ACS Meeting ORL FLOR (1996).
Computer Abstract Biosis AN1996:491867 Ke Et Al “CP-336, 156, A New Estrogen Agonist/Antagonist, Inhibits Bone Turnover and Prevents Bone Loss in Ovariectomized Rats” Bone (New York) (1996) vol. 19 No. 3 Suppl PP 145 S, 1979.
Ginsburg Paul H.
Lilling Herbert J.
Pfizer Inc.
Richardson Peter C.
Sheyka Robert F.
LandOfFree
Microbial biotransformation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microbial biotransformation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microbial biotransformation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2455699